Pharmaceuticals, biotechnology and medical technology are at the core of the Basel Life Sciences cluster. Pharmaceuticals are also Switzerland’s main export contribution with some CHF 98 billion in exports and a market share of about 10% world-wide. In total, the pharmaceutical companies in the Basel region invest about CHF 6 billion per year in research and development. This includes biotech and medtech investments, both of which are gaining in importance. Currently, their sales stand at some CHF 20 billion in Switzerland alone. The pharma, biotech and medtech cluster has also attracted associated industries such as agrochemistry, nanotech and cosmetics.